Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Research

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases

Authors: Rosanna Yeung, Jeremy Hamm, Mitchell Liu, Devin Schellenberg

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Background

In limited metastatic burden of disease, stereotactic body radiotherapy (SBRT) has been shown to achieve high local control rates. It has been hypothesized that SBRT may translate to a better quality of life by delaying the need for systemic chemotherapy and possibly increasing survival. There is limited published literature on the efficacy of SBRT in limited nodal metastases. The primary aim is to review institutional outcomes of patients with solitary or oligometastatic lymph nodes treated with SBRT.

Methods

A retrospective study of patients treated with SBRT to metastatic lymph nodes (March 2010–June 2015) was conducted. Endpoints of this study were local control (LC), chemotherapy-free survival (CFS) following SBRT, toxicities, progression free survival (PFS), and overall survival (OS).

Results

Eighteen patients with a mean age of 65 years underwent SBRT to metastatic lymph nodes. Median follow-up was 33.6 months. There were four hepatocellular carcinoma, seven colorectal, four pancreatic, one esophageal, one gallbladder and one lung primary. Eleven (61%) patients had lymph node metastases at initial presentation of metastatic disease. Seven patients (39%) had systemic therapy prior to SBRT, with five patients receiving two lines of chemotherapy. Eight patients had solitary metastatic disease at the time of radiotherapy. All patients had <5 metastases. Median size of lymph node metastases was 1.95 cm (range: 0.8–6.2 cm). RT doses were 31 to 60 Gy in four to ten fractions, with 44% of patients receiving 35 Gy in 5 fractions. At 1 year, LC was 94% and CFS from SBRT was 60%. One-year PFS and OS were 39% and 89% respectively. There were no grade 3 or higher toxicities.

Conclusions

In this single institution study, SBRT to oligometastatic lymph nodes provided excellent LC and a moderate chemotherapy-free interval with minimal toxicities. Disease progression remains prominent in these patients and larger studies are warranted to identify those who benefit most from SBRT.
Literature
1.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
2.
Weichselbaum RR, Hellman S. Oliometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.PubMed
3.
4.
Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys. 2011;81:831–8.CrossRefPubMed
5.
6.
Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011;47 Suppl 3:S6–22.
7.
Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91:112–20.CrossRefPubMed
8.
Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2055;241:715–24.CrossRef
9.
Sardenberg RA, Figueiredo LP, Haddad FJ, Gross JL, Younes RN. Pulmonary metastasectomy from soft tissue sarcomas. Clinics (Sao Paulo). 2010;65:871–6.CrossRef
10.
Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, The BS, Mayr NA, et al. The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol. 2011;8:405–16.CrossRefPubMed
11.
Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:e28–37.CrossRefPubMed
12.
Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17:1100–7.CrossRefPubMedPubMedCentral
13.
Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic non small-cell lung cancer patients. Ann Oncol. 2014;25:1954–9.CrossRefPubMed
14.
15.
Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, Okunieff P. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650–8.CrossRefPubMed
16.
Benedict SH, Yenice K, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys. 2010;37:4078–101.CrossRefPubMed
17.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
18.
van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448–54.CrossRefPubMed
19.
Todo Y, Kato H, Minobe S, Okamoto K, Suzuki Y, Sudo S, et al. Initial failure site according to primary treatment with or without para-aortic lymphadenectomy in endometrial cancer. Gynecol Oncol. 2011;121(2):314–8.CrossRefPubMed
20.
Bozetti F, Bertario L, Rossetti C, Gennari L, Andreola S, Baratti D, et al. Surgical treatment of locally recurrent rectal carcinoma. Dis Colon Rectum. 1997;40:1421–4.CrossRef
21.
Akasu T, Yamaguchi T, Fujimoto Y, Ishiguro S, Yamamoto S, Fujita S. Abdominal sacral resection for posterior pelvic recurrence of rectal carcinoma: analyses of prognostic factors and recurrence patterns. Ann Surg Oncol. 2007;14:74–83.CrossRefPubMed
22.
Shibata D, Paty PB, Guillem JG, Wong WD, Cohen AM. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum. 2002;45:795–801.CrossRefPubMed
23.
SEO YS, Kim MS, Yoo H, Jang W. Stereotactic body radiotherapy for oligorecurrence within the nodal area from colorectal cancer. World J Gastroeneterol. 2014;20:2005–13.CrossRef
24.
Jereczek-Fossa BA, Ronchi S, Orecchia R. Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother. 2015;20(6):472–83.CrossRefPubMed
25.
Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol. 2014;37:227–33.CrossRefPubMed
26.
Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19:164–70.CrossRefPubMed
27.
Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010;33:157–63.PubMed
28.
Conde-Moreno AJ, Lopez-Fuerra JL, Macias VA, Vázquez de la Torre ML, Samper Ots P, San José-Maderuelo et al. Spanish society of radiation oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases. Clin Transl Oncol 2015; 1–10. Available: https://​doi.​org/​10.​1007/​s12094-015-1383-y.
Metadata
Title
Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
Authors
Rosanna Yeung
Jeremy Hamm
Mitchell Liu
Devin Schellenberg
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0820-1

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue

Research

Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history: a multi-institutional study

Research

Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma

Research

A comprehensive dosimetric study on switching from a Type-B to a Type-C dose algorithm for modern lung SBRT

Research

Correlation between delivered radiation doses to the brainstem or vestibular organ and nausea & vomiting toxicity in patients with head and neck cancers – an observational clinical trial

Research

Patterns of locoregional failure following post-operative intensity-modulated radiotherapy to oral cavity cancer: quantitative spatial and dosimetric analysis using a deformable image registration workflow

Research

Dosimetric comparison of interstitial brachytherapy with multi-channel vaginal cylinder plans in patients with vaginal tumors